ACR适用性标准®:乳腺癌新辅助全身治疗反应的监测
美国放射学会适用性标准针对局部晚期浸润性乳腺癌新辅助化疗后影像学监测反应给出指南。数字乳腺X线、数字乳腺断层合成、超声和MRI是潜在指导患者管理的关键模态,评估受模态、测量技术和肿瘤亚型反应模式影响。指南基于RAND/UCLA适用性方法和GRADE分级,证据不足时辅以专家意见。
要点
- 数字乳腺X线、数字乳腺断层合成、超声和MRI是监测新辅助化疗反应的关键模态。
- 肿瘤大小和治疗反应的评估因所用模态、测量技术及肿瘤亚型反应模式而异。
- 测量技术包括单最长径、三维测量或计算肿瘤体积,反应模式包括同心性缩小或肿瘤碎片化。
核心结论
- 准确的放射学评估有助于局部晚期浸润性乳腺癌新辅助化疗患者的最佳管理和规划。
研究设计与样本
- 美国放射学会适用性标准为针对特定临床情况的循证指南,由多学科专家小组每年审查。
- 指南制定和修订包括对同行评审期刊当前医学文献的广泛分析,并应用RAND/UCLA适用性方法和GRADE分级评估影像和治療程序的适用性。
- 证据缺乏或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。
诊断标准与关键数值
- 数字乳腺X线、数字乳腺断层合成、超声和MRI是监测新辅助化疗反应的关键模态。
- 肿瘤大小和治疗反应的评估因所用模态、测量技术(单最长径、三维测量或计算肿瘤体积)及肿瘤亚型反应模式(同心性缩小或肿瘤碎片化)而异。
局限性
- 证据缺乏或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Patients with locally advanced invasive breast cancers are often treated with neoadjuvant chemotherapy prior to definitive surgical intervention. The primary aims of this approach are to: 1) reduce tumor burden thereby permitting breast conservation rather than mastectomy; 2) promptly treat possible metastatic disease, whether or not it is detectable on preoperative staging; and 3) potentially tailor future chemotherapeutic decisions by monitoring in-vivo tumor response. Accurate radiological assessment permits optimal management and planning in this population. However, assessment of tumor size and response to treatment can vary depending on the modality used, the measurement technique (such as single longest diameter, 3-D measurements, or calculated tumor volume), and varied response of different tumor subtypes to neoadjuvant chemotherapy (such as concentric shrinkage or tumor fragmentation). As discussed in further detail, digital mammography, digital breast tomosynthesis, US and MRI represent the key modalities with potential to help guide patient management. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
引用
- Slanetz PJ, Moy L, Baron P, et al. ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. J Am Coll Radiol. 2017. PMID: 29101985. doi:10.1016/j.jacr.2017.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。